PRINCETON, N.J., Aug. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS) management will present at the 28th Annual Canaccord Adams
Global Growth Conference being held from August 12 - 14, 2008 at the
Intercontinental Hotel in Boston, MA.Schaefer Price, Pharmasset's Chief
Executive Officer, will provide an overview of the company on Tuesday, August
12, 2008 from 11:30 AM - 12:00 PM (ET).
To access a simultaneous webcast of Mr. Price's overview via the internet,
log on to the "Events & Presentations" section of the Investor Center on
Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please
connect to the website at least ten minutes prior to the start of the
presentation to ensure adequate time for a reliable connection and any
software download that may be necessary for the webcast.
A replay of the webcast will be available on Pharmasset's website for
thirty days following the conference. The investor presentation will be
available for download in PDF format immediately following the presentation in
the "Events & Presentations" section of the Investor Center on Pharmasset's
website at http://investor.pharmasset.com/events.cfm .
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
(HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by Bukwang
Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral
treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in
combination with Pegasys(R) plus Copegus(R) through a strategic collaboration
with Roche. Racivir, which is being developed for the treatment of HIV in
combination with other approved HIV drugs, has completed a Phase 2 clinical
trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Contact
Kurt Leutzinger
Chief Financial Officer
kurt.leutzinger@pharmasset.com
Office: +1 (609) 613-4110
.gif)
